BRAF and non-small cell lung carcinoma: In addition, the progression-free survival (PFS) of alectinib was 3 months, which is much lower than the median PFS of alectinib in crizotinib-resistant NSCLC (8 months) in previous clinical trial.[18] As no genetic testing was performed before alectinib administration, we suspected that the BRAF V600E resistance mutation may have been present before the administration of alectinib and lead to a nondurable response to alectinib.